FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC Podcast

Podcast | English | 2025 | 33 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of telisotuzumab vedotin, an antibody-drug conjugate, for NSCLC with high c-MET expression. Dr. Mor Moskovitz and Dr. Jonathan Goldman joined the conversation to help review the data and offer perspective on this new agent.

Podcast Host:

Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA

Podcast Guests:

Jonathan Goldman, MD, Professor of Medicine, UCLA Hematology and Oncology, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development, University of California, Los Angeles, CA, USA
Mor Moskovitz, MD, Head of Thoracic Oncology Service, Davidoff Cancer Center, Beilinson Medical Center, Petah Tikva, Israel